LOS ANGELES, CA - July 15, 2026 (NEWMEDIAWIRE) - Artificial intelligence is becoming an increasingly important component of pharmaceutical research, with companies using machine learning to analyze complex biological data, identify drug targets and improve clinical development decisions. Against that backdrop, VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, announced a collaboration with AI-focused research partner Ardigen that is intended to strengthen development of the company’s BiTAC(R) oncology platform through AI-enabled target discovery and validation (https://ibn.fm/yoDH5).

• Artificial intelligence is becoming an increasingly important tool for drug discovery, with major pharmaceutical companies expanding AI collaborations across oncology and immunology.
• VERAXA Biotech has partnered with AI-focused contract research organization Ardigen to strengthen discovery efforts for its BiTAC(R) cancer therapy platform.
• The collaboration aims to identify optimal dual-target combinations for T-cell engagers and antibody-drug conjugates while reducing development risks.
• VERAXA’s Boolean “AND-gated” BiTAC(R) technology presents a use case that may be particularly well suited for AI-assisted target selection and therapeutic design.
• AI analysis of historical clinical and preclinical datasets could help identify promising targets that were previously abandoned because of safety concerns.
• The partnership reflects a broader trend toward combining computational biology with next-generation antibody therapeutics to improve research productivity.

The agreement brings together VERAXA’s antibody engineering capabilities with Ardigen’s expertise in artificial intelligence, computational biology and bioinformatics. Ardigen, headquartered in Kraków, Poland, with U.S. operations in San Francisco, has supported more than 700 discovery projects for…

Read More

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA

Forward Looking Statements

Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law

This contant was orignally distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Why VERAXA Biotech (VRXA) Could Benefit More Than Others From AI's Growing Impact on Drug R&D.